celz_10q.htm

0001477932-21-003351.txt : 20210517 0001477932-21-003351.hdr.sgml : 20210517 20210517164533 ACCESSION NUMBER: 0001477932-21-003351 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53500 FILM NUMBER: 21931651 BUSINESS ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 BUSINESS PHONE: 833-336-7636 MAIL ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 10-Q 1 celz_10q.htm FORM 10-Q celz_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 000-53500

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada		87-0622284
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

211 E Osborn Road, Phoenix, AZ		85012
(Address of principal executive offices)		(Zip Code)

(833) 336-7636

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports). Yes ☒ No ☐

Indicate by check mark whether the registrant has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock on May 7, 2021, was 1,142,048,685.

		Page Number
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements

	Unaudited Condensed Consolidated Balance Sheets	3

	Unaudited Condensed Consolidated Statements of Operations	4

	Unaudited Condensed Consolidated Statements of Cash Flows	5

	Unaudited Condensed Consolidated Statements of Stockholder’ (deficit)	6

	Notes to Unaudited Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19

Item 4.	Controls and Procedures	19

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 6.	Exhibits	20

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2021			December 31, 2020
ASSETS
CURRENT ASSETS
Cash	$	275,134		$	98,012
Total Current Assets		275,134			98,012

OTHER ASSETS
Licenses, net of amortization		596,742			619,763
TOTAL ASSETS	$	871,876		$	717,775

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable	$	356,001		$	350,899
Accrued expenses		67,763			159,771
Management fee and patent liabilities - related parties		255,082			468,782
Convertible notes payable, net of discount of $335,567 and $409,649, respectively		327,225			788,701
Advances from related party		32,800			10,800
Derivative liabilities		2,275,578			38,741,832
Total Current Liabilities		3,314,449			40,520,785

Commitments and contingencies

STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value, 7,000,000 and 7,000,000 shares authorized, no shares issued and outstanding at March 31, 2021 and December 31, 2020		-			-
Series A preferred stock, $0.001 par value, 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at March 31, 2021 and December 31, 2020		3,000			3,000
Series B preferred stock, $0.001 par value, 1,000 shares authorized, 350 and 0 shares issued and outstanding at March 31, 2021 and December 31, 2020. Liquidation preference of $420,000.		326,600			-
Series C preferred stock, $0.001 par value, 500 shares authorized, 150 and 0 shares issued and outstanding at March 31, 2021 and December 31, 2020. Liquidation preference of $180,000.		141,049			-
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 1,140,083,954 and 768,540,617 issued and 1,140,079,954 and 768,536,617 outstanding at March 31, 2021 and December 31, 2020, respectively		1,140,080			768,536
Additional paid-in capital		30,000,915			21,315,690
Accumulated deficit		(34,054,217	)		(61,890,236	)
TOTAL STOCKHOLDERS' DEFICIT		(2,442,573	)		(39,803,010	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	871,876		$	717,775

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended March 31, 2021			For the Three Months Ended March 31, 2020

Revenues	$	-		$	42,100

Cost of revenues		-			14,196

Gross profit		-			27,904

OPERATING EXPENSES
Selling, general and administrative		280,923			346,168
Amortization of patent costs		23,021			16,772
TOTAL EXPENSES		303,944			362,940

Operating loss		(303,944	)		(335,036	)

OTHER INCOME/(EXPENSE)
Interest expense		(336,076	)		(323,223	)
Gain loss on extinguishment of convertible notes		-			-
Change in fair value of derivatives liabilities		28,476,039			4,400,739
Total other income (expense)		28,139,963			4,077,516

INCOME BEFORE PROVISION FOR INCOME TAXES		27,836,019			3,742,480

Provision for income taxes		-			-

NET INCOME	$	27,836,019		$	3,742,480

BASIC NET INCOME PER SHARE	$	0.02		$	0.09

DILUTED NET INCOME PER SHARE	$	0.02		$	0.00

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC		1,138,560,486			40,746,192

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED		1,244,529,602			776,604,919

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Three Months Ended March 31, 2021			For the Three Months Ended March 31, 2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	27,836,019		$	3,742,480
Adjustments to reconcile net loss to net cash from operating activities:
Amortization		23,021			16,772
Amortization of debt discounts		231,232			289,825
Change in fair value of derivatives liabilities		(28,476,039	)		(4,400,739	)
Increase in principal and accrued interest balances due to penalty provision		93,821			-
Changes in assets and liabilities:
Accounts receivable		-			(2,800	)
Inventory		-			(2,800	)
Accounts payable		5,102			65,780
Accrued expenses		9,026			46,898
Management fee payable		(163,700	)		49,263
Net cash used in operating activities		(441,518	)		(195,321	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable		134,640			145,000
Proceeds from sale of preferred stock		462,000			-
Related party advances		22,000			-
Net cash provided from financing activities		618,640			145,000

NET INCREASE (DECREASE) IN CASH		177,122			(50,321	)
BEGINNING CASH BALANCE		98,012			88,648
ENDING CASH BALANCE	$	275,134		$	38,327

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	-		$	6,000
Cash payments for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued interest and derivative liabilities into common stock	$	9,012,418		$	1,101,764
Conversion of management fees and patent liability into common stock	$	50,000		$	45,000
Discounts on convertible notes payable due to derivative liabilities	$	134,640		$	145,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
December 31, 2020		3,000,000	$	3,000		-	$	-		-	$	-		768,536,617	$	768,536	$	21,315,690		$	(61,890,236	)	$	(39,803,010	)

Proceeds from sales of preferred stock		-		-		350		321,000		150		141,000		2,142,857		2,143		(2,143	)		-			462,000

Common stock issued for related party patent and management liabilities		-		-		-		-		-		-		44,642,847		44,643		5,357			-			50,000

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		-		-		-		-		314,702,077		314,702		572,861			-			887,563

Relief of derivative liabilities		-		-		-		-		-		-		-		-		8,124,855			-			8,124,855

Dividends on preferred stock		-		-		-		5,600		-		49		-		-		(5,649	)		-			-

Cashless exercise of warrants		-		-		-		-		-		-		10,055,556		10,056		(10,056	)		-			-

Net income		-		-		-		-		-		-		-		-		-			27,836,019			27,836,019

March 31, 2021		3,000,000	$	3,000		350	$	326,600		150	$	141,049		1,140,079,954	$	1,140,080	$	30,000,915		$	(34,054,217	)	$	(2,442,573	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
December 31, 2019		3,000,000	$	3,000		-	$	-		-	$	-		22,489,046	$	22,489	$	17,468,018		$	(25,565,006	)	$	(8,071,499	)

Common stock issued for related party management liabilities		-		-		-		-		-		-		2,250,000		2,250		42,750			-			45,000

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		-		-		-		-		61,016,388		61,016		289,531			-			350,547

Relief of derivative liabilities		-		-		-		-		-		-		-		-		751,217			-			751,217

Difference in shares from reverse stock split		-		-		-		-		-		-		1,293		2		(2	)		-			-

Net income		-		-		-		-		-		-		-		-		-			3,742,480			3,742,480

March 31, 2020		3,000,000	$	3,000		-	$	-		-	$	-		85,756,727	$	85,757	$	18,551,514		$	(21,822,526	)	$	(3,182,255	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2021

Introductory Comment

Unless otherwise indicated, any reference to “our company”, “we”, “us”, or “our” refers to Creative Medical Technology Holdings, Inc., and as applicable to its wholly owned subsidiary, Creative Medical Technologies, Inc., a Nevada corporation (“CMT”).

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization – Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments.

We currently conduct substantially all of our commercial operations through CMT. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 14 locations in the United States and Europe.

In 2020, we formed ImmCelz, Inc., a wholly owned subsidiary of CMT. Through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

We are currently primarily focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, commercializing our StemSpine® treatment for lower back pain and filing an Innovative New Drug (IND) application to the FDA utilizing our ImmCelz technology platform to treat stroke. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products such as Ovastem™ that utilize our proprietary intellectual property.

Table of Contents

Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2021 and for the three-month period then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results for the full year.

Going Concern – The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the three-month period ended March 31, 2021, the Company had negative cash flows from operating activities of $441,518 and had a working capital deficit of $3,039,315. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Risks and Uncertainties - On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

Revenue - We have adopted the new revenue recognition standards that went into effect on January 1, 2019. All revenues reported in 2019 and beyond reflect those standards. Adoption of the standards had no effect on the Company’s revenues.

Fair Value of Financial Instruments - The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2021, and December 31, 2020, the Company didn’t have any Level 1 or 2 financial instruments. The table below reflects the results of our Level 3 fair value calculations:

	Notes			Warrants		Total
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832
Addition of new conversion option derivatives		817,791			-		817,791
Extinguishment/modification		-			-		-
Conversion of note derivatives		(8,124,855	)		-		(8,124,855	)
Change in fair value		(29,438,447	)		279,257		(29,159,190	)
Derivative liability at March 31, 2021	$	598,324		$	1,677,254	$	2,275,578

Table of Contents

Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the three-months ended March 31, 2021.

	For the Three Months Ended March 31, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		1,138,560,486
Effect of Series B and C preferred stock		12,000,000
Effect of warrants		64,785,779
Effect of convertible notes payable		28,949,143
Effect of convertible related party management fee and patent liabilities		234,194
Weighted average common shares outstanding used in calculating diluted earnings per share		1,244,529,602

Net income as reported	$	27,836,019
Add - Interest on convertible notes payable		53,718
Net income available to common stockholders	$	27,889,737

	For the Three Months Ended March 31, 2020
Weighted average common shares outstanding used in calculating basic earnings per share		40,746,192
Effect of warrants		4,834,433
Effect of convertible notes payable		562,263,144
Effect of convertible related party management fee and patent liabilities		168,761,150
Weighted average common shares outstanding used in calculating diluted earnings per share		776,604,919

Net income as reported	$	3,742,480
Add - Interest on convertible notes payable		49,714
Net income available to common stockholders	$	3,792,194

The Company excluded 3,333 options and 8,920,779 warrants from the computation of diluted net income per share for the three-months ended March 31, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.

During the three-month period ended March 31, 2020, the Company had 3,333 options and 209,827 warrants to purchase common stock outstanding. In addition, the Company has various convertible notes payable which on March 31, 2020, are convertible into approximately 562,263,144 shares of common stock.

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

Table of Contents

NOTE 2 – LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH. Amortization expense of $2,493 was recorded for the three-month period ended March 31, 2021. As of March 31, 2021, and December 31, 2020, the carrying value of the patent was $48,466 and $50,959, respectively. The Company expects to amortize approximately $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - In August 2016, CMT entered into a License Agreement with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of March 31, 2021, and December 31, 2020, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $293 was recorded for the three-month period ended March 31, 2021. Amortization expense of $294 was recorded for the three-month period ended March 31, 2020. As of March 31, 2021, and December 31, 2020, the carrying values of the patent were $5,256 and $5,549, respectively. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.

Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

	•	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	•	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.

$200,000, upon completion of the IRB clinical trial.

$300,00 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

•

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

$100,000 upon filing an IND with the FDA.

$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.

$400,000 upon dosing the first patient in a Phase 3 clinical trial.

	•	Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.
	•	In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.
	•	For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

Table of Contents

The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $2,500 was recorded for the three-month period ended March 31, 2021. As of March 31, 2021, and December 31, 2020, the carrying value of the initial patent license was $62,500 and $65,000, respectively. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

In November 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. During the three months ended March 31, 2021, $50,000 of this amount was converted into 44,642,847 shares of the Company’s common stock. As of March 31, 2021, the remaining liability balance was $0. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 was recorded for the three-month period ended March 31, 2021. Amortization expense of $11,485 was recorded for the three-month period ended March 31, 2020, As of March 31, 2021 and December 31, 2020, the carrying value of the patent was $236,769 and $248,254, respectively. The Company expect to amortize approximately $46,000 annually through 2027 related to the patent costs.

ImmCelz^TM - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. The Agreement grants to ImmCelz^TM the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz^TM access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor and as documented in standard operating procedures (SOPs) and other written documentation. The terms of the agreement are as follows:

Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz^TM. during such calendar quarter (the “Continuing Royalty”)

in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above.

The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $6,250 was recorded for the three-month period ended March 31, 2021. There was no amortization expense recorded for the three-month period ended March 31, 2020. As of March 31, 2021, and December 31, 2020, the carrying values of the patent were $243,750 and $250,000, respectively. The Company expects to amortize approximately $25,000 annually through 2030 related to the licensing costs.

Table of Contents

NOTE 3 – RELATED PARTY TRANSACTIONS

The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2019. Each of the Company’s executive officers is employed by CMH and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. During the three months ended March 31, 2021 and 2020, the Company recorded $135,000 in expense in connection with this agreement.

As of March 31, 2021, and December 31, 2020, amounts due to CMH under the arrangement were $5,082 and $18,782, respectively.

See Note 2 for discussion of an additional related party transaction with CMH.

NOTE 4 – DEBT

During the three-months ended March 31, 2021, we issued $157,150 in convertible notes to accredited investors with net proceeds of $134,640. The notes mature during February of 2022 and bear interest at rate of 8%. The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is amortizing the discount due to derivative liabilities and on-issuance discount totaling $157,150 to interest expense using the straight-line method over the original terms of the loans.

During the three-months ended March 31, 2021 and 2020, the Company amortized $231,232 and $289,825 respectively, to interest expense. As of March 31, 2021, total discounts of $335,568 remained for which will be expensed through February 2022.

During the three-months ended March 31, 2021, the Company issued an aggregate of 314,702,077 shares upon the conversion of $887,560 of outstanding principal, interest and fees on existing, outstanding notes and 10,055,556 shares upon the cashless exercise of 11,583,333 warrants. During the three months ended March 31, 2020, the Company issued an aggregate of 61,016,388 shares upon the conversion of $350,547 of outstanding principal, interest and fees on existing, outstanding notes.

During the three-months ended March 31, 2021 and 2020, the Company did not extinguish any principal or interest.

As of March 31, 2021, future loan maturities are as follows:

For the year ended December 31,

2021		505,642
2022		157,150
Total	$	662,792

Table of Contents

NOTE 5 – DERIVATIVE LIABILITIES

Derivative Liabilities

In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the three-months ended March 31, 2021, the Company recorded initial derivative liabilities of $817,791 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0106 to $0.0138 our stock price on the date of grant of $0.0310 to $0.0138, expected dividend yield of 0%, expected volatility of 98.14%, risk free interest rate of 0.10% and expected terms of 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $683,151, which was recorded as a day one loss in derivative liability.

On March 31, 2021, the derivative liabilities were revalued at $2,275,578 resulting in a gain of $29,159,190 related to the change in fair market value of the derivative liabilities during the three months ended March 31, 2021. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.0008 to 3.0900, our stock price on the date of valuation ($0.0332), expected dividend yield of 0%, expected volatility of 93.05% to 102.96%, risk-free interest rate of 0.07% to 0.35%, and expected terms ranging from 0.5 to 3.3 years.

In connection with convertible notes converted, as disclosed in Note 4, the Company reclassed derivative liabilities with a fair value of $8,124,855 to additional paid-in capital for the three-month period ended March 31, 2021. The Company revalued the derivative liabilities at each conversion date recording the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted to the pre-conversion carrying value to additional paid-in capital.

Future Potential Dilution

Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of March 31, 2021, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 37 million shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

NOTE 6 – WARRANTS

From January 2021 through March 2021, the Company issued no warrants in connection with services and convertible notes payable.

The fair value of each warrant is estimated using the Black-Scholes valuation model on the date of issuance and if needed at each period end. Assumptions used in calculating the fair value during the three months ended March 31, 2021 were as follows:

		Weighted Average Inputs Used

Annual dividend yield	$		-
Expected life (years)			1.3 to 3.3
Risk-free interest rate			0.07% to 0.35	%
Expected volatility			93.05% to 102.96	%
Common stock price	$		0.0008 to $3.0900

Since the expected life of the warrants was greater than the Company’s historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies.

The issuances, exercises and pricing re-sets during the three months ended March 31, 2021, are as follows:

Outstanding at December 31, 2020		76,369,112
Issuances		-
Exercises		(11,583,333	)
Anti-Dilution/Modification		-
Forfeitures/cancellations		-
Outstanding at March 31, 2021		64,785,779
Weighted Average Price at March 31, 2021	$	0.006

Table of Contents

NOTE 7 – STOCKHOLDERS’ DEFICIT

Series B Convertible Preferred Stock Equity Financing

On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation.

Dividends: Each share of Series B Convertible Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 10% per annum, payable quarterly, beginning on the Original Issuance Date and ending on the date that such share of Series B Convertible Preferred Share has been converted or redeemed (the “Dividend End Date”). Dividends may be paid in cash or in shares of Series B Convertible Preferred Stock. From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series B Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous sentence.

Voting Rights: The Series B Convertible Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not in excess of 4.99% conversion limitation). However, as long as any shares of Series B Convertible Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series B Convertible Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Convertible Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series B Convertible Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series b Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (d) increase the number of authorized shares of Series B Convertible Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.

Liquidation: Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

Conversion: Each share of Series B Convertible Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value of such share of Series B Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series B Convertible Preferred Stock shall be the amount equal to $0.05 per share. Following the event of a default the conversion price shall be $0.35.

Table of Contents

Redemption: The Series B Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.

105% of the stated value if the redemption takes place within 90 days of issuance;

110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance

120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance

In addition, the Series B Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages.

Most Favored Nation Provision. From the date hereof until the date when the Holder no longer holds any shares of Series B Preferred Stock, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a “Subsequent Financing”), the Holder may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series B Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. The Company shall provide the Holder with notice of any such Subsequent Financing in the manner set forth below. For purposes of illustration, if a Subsequent Financing were to occur whereby the Company sells and issues a convertible note with a conversion price that includes a discount to the market price of its Common Stock, the Holder will be entitled to receive the same convertible note on the exact same terms on a dollar-for-dollar basis via the exchange of the Series B Preferred Stock the Holder holds on the date of the sale and issuance of the convertible note.

On February 12, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with BHP Capital, LLC (“BHP”) in the amount of $350,000 for 350 shares of the newly-designated Series B Convertible Preferred Stock valued at $1,200 per share for which $326,600 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 1.5 million shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.

Series C Convertible Preferred Stock Equity Financing

On March 30, 2021, the Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation.

Dividends: Each share of Series C Convertible Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 10% per annum, payable quarterly, beginning on the Original Issuance Date and ending on the date that such share of Series C Convertible Preferred Share has been converted or redeemed (the “Dividend End Date”). Dividends may be paid in cash or in shares of Series C Convertible Preferred Stock. From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series C Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous sentence.

Table of Contents

Voting Rights: The Series C Convertible Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not in excess of 4.99% conversion limitation). However, as long as any shares of Series C Convertible Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series C Convertible Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series C Convertible Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series C Convertible Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series C Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (d) increase the number of authorized shares of Series C Convertible Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.

Liquidation: Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series C Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

Conversion: Each share of Series C Convertible Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value of such share of Series C Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series C Convertible Preferred Stock shall be the amount equal to $0.05 per share. Following the event of a default the conversion price shall be $0.35.

Redemption: The Series C Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.

105% of the stated value if the redemption takes place within 90 days of issuance;

110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance

120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance

In addition, the Series C Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages.

Most Favored Nation Provision. From the date hereof until the date when the Holder no longer holds any shares of Series C Preferred Stock, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a “Subsequent Financing”), the Holder may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series C Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. The Company shall provide the Holder with notice of any such Subsequent Financing in the manner set forth below. For purposes of illustration, if a Subsequent Financing were to occur whereby the Company sells and issues a convertible note with a conversion price that includes a discount to the market price of its Common Stock, the Holder will be entitled to receive the same convertible note on the exact same terms on a dollar-for-dollar basis via the exchange of the Series C Preferred Stock the Holder holds on the date of the sale and issuance of the convertible note.

On March 30, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with Fourth Man, LLC (“FM”) in the amount of $150,000. The closing under the SPA consisted of 150 shares of Series C Convertible Preferred Stock, stated value $1,200 per share, issued to FM for a purchase price of $150,000, or $1,000 per share, for which $141,049 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 642,857 shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC 855, management reviewed all material events through May 17, 2021, for these financial statements and there are no material subsequent events to report, except as follows:

Conversion Notice

During April and May of 2021, we issued 4,948,065 shares of common stock for the conversion of $97,697 in convertible notes.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2020, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Table of Contents

Overview

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. We were incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, we completed a reverse merger transaction under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became our wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became our principal stockholder. In connection with this merger, we changed our name to Creative Medical Technologies Holdings, Inc. to reflect our current business.

CMT was originally created as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain and liver disease using various types of stem cells through our ImmCelz, Inc., AmnioStem LLC and StemSpine, LLC subsidiaries. However, neither ImmCelz LLC, AmnioStem LLC nor StemSpine LLC have commenced commercial activities.

We are currently primarily focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, commercializing our StemSpine® treatment for lower back pain and filing an Innovative New Drug (IND) application to the FDA utilizing our ImmCelz technology platform to treat stroke. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our proprietary intellectual property.

Our principal executive offices are located at 211 E Osborn Road, Phoenix, AZ 85012.

During the first three-months of 2021, we issued $157,150 in convertible notes with net proceeds of $134,640 to accredited investors.

During the three-month period ending March 31, 2021, we incurred interest expense of $61,354 arising from the third-party notes of $662,792.

Table of Contents

Plan of Operations

We commenced marketing disposable stem cell concentration kits for the CaverStem® erectile dysfunction treatment in the fourth quarter of 2017 and the FemCelz® female sexual dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of 2019. We also continued filed an Innovative New Drug (IND) application for the ImmCelz™ product to treat stroke. We have commenced physician recruitment to build a 100-patient treatment registry to support our StemSpine^® commercialization. For the next 12 months our plan of operations is to continue to expand the market for the CaverStem® and FemCelz® procedures, build the StemSpine patient registry, and coordinate with the FDA to authorize the commencement of the ImmCelz Phase I trial. As of March 31, 2021, we had approximately $275,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least June 2021. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Results of Operations – For the Three-month Period Ended March 31, 2021 and 2020

Gross Revenue. We generated no gross revenue for the three-month period ended March 31, 2021, in comparison with $42,500 for the comparable quarter a year ago. The decrease of $42,500 or 100% reflects the ongoing negative impact of the COVID-19 pandemic.

Cost of Goods Sold. We generated no cost of goods sold for the three-month period ended March 31, 2021, in comparison with $14,196 for the comparable quarter a year ago. The decrease of $14,196 or 100% is due to the lack of sales in the quarter.

Gross Profit/(Loss). We generated no gross profit for the three-month period ended March 31, 2021, in comparison with $27,904 for the comparable quarter a year ago. The decrease of $27,904 or 100% is due to the lack of sales in the quarter.

General and Administrative Expenses. General and administrative expenses for the three-month period ended March 31, 2021, totaled $280,293 in comparison with $346,168, for the comparable quarter a year ago. The decrease of $65,245 or 19% is primarily due to a decrease of $20,131 in marketing, $18,336 in legal and $21,431 in accounting expenses.

Amortization Expenses. Amortization expenses for the three-month period ended March 31, 2021, totaled $23,021 in comparison with $16,772, for the comparable quarter a year ago. The increase of $6,249 or 37% is due to the added amortization of the $250,000 Jadi Cell asset.

Research and Development Expenses. There were no research and development expenses for the three-month period ended March 31, 2021, and for the comparable quarter a year ago.

Other Income / Expense. Other income for the three-month period ended March 31, 2021, totaled $28,139,963 in comparison with $4,077,516, for the comparable quarter a year ago. The increased income of $24,062,447, or 590% is primarily due to a gain in the fair value of derivative liabilities of $28,476,039, compared to a gain of $4,400,739 for the comparable quarter a year ago.

Net Income/Loss. For the reasons stated above, our net income for the three-month period ended March 31, 2021, totaled $27,836,019 in comparison to $3,742,480, for the comparable quarter a year ago.

Liquidity and Capital Resources

Our principal source of liquidity has been funds received from the sale of our common and preferred stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by equity investments, funds to be loaned to us by third parties and revenues generated from our Caverstem^® ED and FemCelz^® vaginal rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

Table of Contents

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments, building the StemSpine patient registry and initiating the ImmCelz Phase I clinical trial.

For the next 12 months our plan of operations is to market our disposable kits, partner with leading physicians to build the StemSpine patient registry and initiate the ImmCelz Phase I clinical trial. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Cash Flows

Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $441,518 for the three-month period ended March 31, 2021 in comparison to $195,321 for the comparable period a year ago, a decrease of $246,197 or 126%. The increase in cash used in operations was primarily related to a $212,963 increase in payments owed to CMH and a $60,678 decrease in accounts payable.

Net Cash used in Investing Activities. There was no cash used in investing activities in the three-month period ended March 31, 2021 and March 31, 2020, respectively.

Net Cash From Financing Activities. In the three-month period ended March 31, 2021, we raised $618,640 through the issuance of convertible debt, preferred stock and a related party advance. In the three-month period ended March 31, 2020, we raised $145,000 through the issuance of convertible debt. The $473,640 or 327% increase in cash flows from financing activities were primarily related to the proceeds from the sale of preferred stock.

Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2021, the Company had $275,000 of available cash and a working capital deficit of $3,039,315. For the three-month period ended March 31, 2021, the Company had no revenue, $303,944 in operating loss and used net cash for operating activities of $441,518. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2021.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. In April 2016, the Company entered into an agreement with a third party to perform banking services. The banking services did not materialize and thus the Company cancelled the agreement in June 2016. The Company and the third party are currently in a dispute as to fees under the agreement. The Company believes no consideration is due as the services were not performed. Any proposed litigation or equivalent will be vigorously defended for which the Company expects to prevail. As of the date of these financial statements the Company has not recorded a loss provision as the amount is not probable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Convertible Notes/Debentures

During the three-months ended March 31, 2021, we issued convertible promissory notes in the face amount of $157,150 to multiple lenders for which we received proceeds of $144,500. The notes bear interest of 8% which would increase up to 24% in the event of default and have maturity dates in February, 2022. The notes are convertible at rates ranging from 60% to 71% of either the average of the two lowest traded prices of our common stock during the prior 15 trading days preceding the conversion date or the average of the two lowest traded prices of our common stock during the prior 15 trading days preceding the conversion date. We have the option to redeem the notes, in whole or in part, on $144,150 of the face amount of the issued convertible promissory notes for premiums ranging from 0% to 125% of the outstanding principle and interest up to 180 days from the date of issuance. After 180 days the right of repayment expires.

On February 12, 2021, pursuant to the terms identified in Note 7 above, the Company entered into a new preferred equity financing agreement with BHP Capital, LLC (“BHP”) in the amount of $350,000 for 350 shares of the newly-designated Series B Convertible Preferred Stock valued at $1,200 per share for which $326,600 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 1.5 million shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.

On March 30, 2021, pursuant to the terms identified in Note 7, the Company entered into a new preferred equity financing agreement with Fourth Man, LLC (“FM”) in the amount of $150,000. The closing under the SPA consisted of 150 shares of Series C Convertible Preferred Stock, stated value $1,200 per share, issued to FM for a purchase price of $150,000, or $1,000 per share, for which $141,049 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 642,857 shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.

Item 6. Exhibits

SEC Ref. No.		Title of Document
31.1		Rule 13a-14(a) Certification by Principal Executive Officer
31.2		Rule 13a-14(a) Certification by Principal Financial Officer
32.1		Section 1350 Certification of Principal Executive Officer
32.2		Section 1350 Certification of Principal Financial Officer
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Creative Medical Technology Holdings, Inc.

Date: May 17, 2021	By	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: May 17, 2021	By	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 celz_ex311.htm CERTIFICATION celz_ex311.htm

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Timothy Warbington, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended March 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 17, 2021	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 celz_ex312.htm CERTIFICATION celz_ex312.htm

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Donald Dickerson, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended March 31, 2021;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 17, 2021	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 celz_ex321.htm CERTIFICATION celz_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Timothy Warbington, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ended March 31, 2021, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Quarterly Report on Form 10-Q for the period ended March 31, 2021 fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc.

Date: May 17, 2021	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 celz_ex322.htm CERTIFICATION celz_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Donald Dickerson, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ended March 31, 2021, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Quarterly Report on Form 10-Q for the period ended March 31, 2021, fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc.

Date: May 17, 2021	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 celz-20210331.xml XBRL INSTANCE DOCUMENT 0001187953 2021-01-01 2021-03-31 0001187953 us-gaap:SubsequentEventMember 2021-04-01 2021-05-31 0001187953 celz:FourthManLLCMember 2021-03-30 0001187953 celz:FourthManLLCMember 2021-03-31 0001187953 celz:SeriesCPreferredStockSharesMember 2021-02-11 0001187953 celz:SeriesCPreferredStockSharesMember 2021-01-01 2021-03-31 0001187953 celz:BHPCapitalLLCMember 2021-02-01 2021-02-12 0001187953 celz:SeriesPreferredStockSharesMember 2021-03-31 0001187953 celz:BHPCapitalLLCMember 2021-02-12 0001187953 celz:SeriesPreferredStockSharesMember 2021-02-11 0001187953 celz:SeriesPreferredStockSharesMember 2021-01-01 2021-03-31 0001187953 celz:BoardOfDirectorsMember 2021-02-11 0001187953 celz:WarrantsMember celz:MaximumRangeMember 2021-03-31 0001187953 celz:WarrantsMember celz:MinimumRangeMember 2021-03-31 0001187953 celz:WarrantsMember celz:MaximumRangeMember 2021-01-01 2021-03-31 0001187953 celz:WarrantsMember celz:MinimumRangeMember 2021-01-01 2021-03-31 0001187953 celz:RevaluationMember celz:MaximumRangeMember 2021-03-31 0001187953 celz:RevaluationMember celz:MinimumRangeMember 2021-03-31 0001187953 celz:RevaluationMember celz:MaximumRangeMember 2021-01-01 2021-03-31 0001187953 celz:RevaluationMember celz:MinimumRangeMember 2021-01-01 2021-03-31 0001187953 celz:InitialValuationMember celz:MaximumRangeMember 2021-03-31 0001187953 celz:InitialValuationMember celz:MinimumRangeMember 2021-03-31 0001187953 celz:InitialValuationMember 2021-01-01 2021-03-31 0001187953 celz:RevaluationMember 2021-01-01 2021-03-31 0001187953 celz:RevaluationMember 2021-03-31 0001187953 us-gaap:ConvertibleDebtMember celz:AccreditedInvestorsMember celz:MaximumRangeMember 2021-01-01 2021-03-31 0001187953 us-gaap:ConvertibleDebtMember celz:AccreditedInvestorsMember celz:MinimumRangeMember 2021-01-01 2021-03-31 0001187953 us-gaap:ConvertibleDebtMember celz:AccreditedInvestorsMember 2021-03-31 0001187953 us-gaap:ConvertibleDebtMember celz:AccreditedInvestorsMember 2021-01-01 2021-03-31 0001187953 celz:CreativeMedicalHealthsMember 2020-01-01 2020-03-31 0001187953 celz:CreativeMedicalHealthsMember 2021-01-01 2021-03-31 0001187953 celz:CreativeMedicalHealthsMember 2020-12-31 0001187953 celz:CreativeMedicalHealthsMember 2021-03-31 0001187953 celz:CreativeMedicalHealthsMember 2017-11-01 2017-11-17 0001187953 srt:MinimumMember 2018-12-01 2018-12-31 0001187953 srt:MaximumMember 2018-12-01 2018-12-31 0001187953 celz:JanuaryTwoZeroOneSixMember 2021-01-01 2021-03-31 0001187953 celz:StemspineLLCMember 2017-05-01 2017-05-17 0001187953 celz:CreativeMedicalHealthIncMember us-gaap:PatentsMember celz:ScenarioTwoMember 2017-05-01 2017-05-17 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember celz:ScenarioOneMember 2017-05-01 2017-05-17 0001187953 us-gaap:PatentsMember 2020-12-31 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2020-12-31 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2021-03-31 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2020-01-01 2020-03-31 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2021-01-01 2021-03-31 0001187953 us-gaap:PatentsMember celz:StemspineLLCMember 2021-03-31 0001187953 us-gaap:PatentsMember celz:StemspineLLCMember 2020-12-31 0001187953 us-gaap:PatentsMember celz:StemspineLLCMember 2021-01-01 2021-03-31 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2017-05-17 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2017-05-01 2017-05-17 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2019-11-01 2019-11-30 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2021-03-31 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2020-12-31 0001187953 us-gaap:PatentsMember celz:CreativeMedicalHealthIncMember 2021-01-01 2021-03-31 0001187953 celz:PatentLicenseAgreementMember 2020-12-31 0001187953 celz:PatentLicenseAgreementMember 2021-03-31 0001187953 celz:PatentLicenseAgreementMember 2021-01-01 2021-03-31 0001187953 us-gaap:PatentsMember 2021-03-31 0001187953 us-gaap:PatentsMember 2021-01-01 2021-03-31 0001187953 2020-12-01 2020-12-28 0001187953 celz:WarrantsMember 2020-01-01 2020-03-31 0001187953 celz:OptionsMember 2020-01-01 2020-03-31 0001187953 celz:OptionsMember 2021-01-01 2021-03-31 0001187953 celz:WarrantsMember 2021-03-31 0001187953 celz:WarrantsMember 2021-01-01 2021-03-31 0001187953 celz:WarrantsMember 2020-12-31 0001187953 celz:NotesMember 2021-03-31 0001187953 celz:NotesMember 2021-01-01 2021-03-31 0001187953 celz:NotesMember 2020-12-31 0001187953 us-gaap:RetainedEarningsMember 2021-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001187953 us-gaap:CommonStockMember 2021-03-31 0001187953 celz:SeriesCPreferredStocksMember 2021-03-31 0001187953 celz:SeriesBPreferredStocksMember 2021-03-31 0001187953 celz:SeriesAPreferredSharesMember 2021-03-31 0001187953 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001187953 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001187953 celz:SeriesCPreferredStocksMember 2021-01-01 2021-03-31 0001187953 celz:SeriesBPreferredStocksMember 2021-01-01 2021-03-31 0001187953 celz:SeriesAPreferredSharesMember 2021-01-01 2021-03-31 0001187953 us-gaap:RetainedEarningsMember 2020-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001187953 us-gaap:CommonStockMember 2020-12-31 0001187953 celz:SeriesCPreferredStocksMember 2020-12-31 0001187953 celz:SeriesBPreferredStocksMember 2020-12-31 0001187953 celz:SeriesAPreferredSharesMember 2020-12-31 0001187953 us-gaap:RetainedEarningsMember 2020-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001187953 us-gaap:CommonStockMember 2020-03-31 0001187953 celz:SeriesCPreferredStocksMember 2020-03-31 0001187953 celz:SeriesBPreferredStocksMember 2020-03-31 0001187953 celz:SeriesAPreferredSharesMember 2020-03-31 0001187953 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001187953 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001187953 celz:SeriesCPreferredStocksMember 2020-01-01 2020-03-31 0001187953 celz:SeriesBPreferredStocksMember 2020-01-01 2020-03-31 0001187953 celz:SeriesAPreferredSharesMember 2020-01-01 2020-03-31 0001187953 us-gaap:RetainedEarningsMember 2019-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001187953 us-gaap:CommonStockMember 2019-12-31 0001187953 celz:SeriesCPreferredStocksMember 2019-12-31 0001187953 celz:SeriesBPreferredStocksMember 2019-12-31 0001187953 celz:SeriesAPreferredSharesMember 2019-12-31 0001187953 2020-03-31 0001187953 2019-12-31 0001187953 2020-01-01 2020-03-31 0001187953 us-gaap:PreferredClassAMember 2021-03-31 0001187953 us-gaap:PreferredClassAMember 2020-12-31 0001187953 celz:SeriesBPreferredStockSharesMember 2020-12-31 0001187953 celz:SeriesBPreferredStockSharesMember 2021-03-31 0001187953 celz:PreferredStockAMember 2020-12-31 0001187953 celz:PreferredStockAMember 2021-03-31 0001187953 celz:SeriesCPreferredStockSharesMember 2020-12-31 0001187953 celz:SeriesCPreferredStockSharesMember 2021-03-31 0001187953 celz:PreferredStockSeriesBMember 2020-12-31 0001187953 celz:PreferredStockSeriesBMember 2021-03-31 0001187953 2020-12-31 0001187953 2021-03-31 0001187953 2021-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure celz:integer CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 0001187953 10-Q false --12-31 true false true Yes 2021-03-31 Non-accelerated Filer Q1 2021 true 1142048685 true false Yes

275134

98012

275134

98012

596742

619763

871876

717775

356001

350899

67763

159771

255082

468782

327225

788701

32800

10800

2275578

38741832

3314449

40520785

1140080

768536

30000915

21315690

-34054217

-61890236

-2442573

-39803010

871876

717775

326600

141049

3000

409649

335567

0.001

6000000000

768540617

1140083954

150

768536617

500

0.001

150

180000

1140079954

1000

0.001

350

420000

0.001

7000000

0.001

3000000

42100

14196

27904

280923

346168

23021

16772

303944

362940

-303944

-335036

336076

323223

28476039

4400739

28139963

4077516

27836019

3742480

27836019

3742480

0.02

0.09

0.02

0.00

1138560486

40746192

1244529602

776604919

231232

289825

-28476039 -4400739

93821

-2800

5102

65780

9026

46898

-163700

49263

-441518

-195321

134640

145000

462000

22000

618640

145000

177122

-50321

88648

38327

6000

9012418 1101764 50000 45000 134640 145000

3000000

22489046

3000

22489

17468018

-25565006

-8071499

2250000

2250

42750

45000

61016388

61016

289531

350547

751217

1293

-2

3742480

3000000

85756727

3000

85757

18551514

-21822526

-3182255

3000000

768536617

3000

768536

21315690

-61890236

350 150 2142857

321000

141000

2143

-2143

462000

44642847

44643

5357

50000

314702077

314702

572861

887563

8124855

5600

-5649

10055556

10056

-10056

27836019

3000000

350

150

1140079954

3000

326600

141049

1140080

30000915

-34054217

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Organization – Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments.   We currently conduct substantially all of our commercial operations through CMT. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 14 locations in the United States and Europe.     In 2020, we formed ImmCelz, Inc., a wholly owned subsidiary of CMT. Through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.        We are currently primarily focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, commercializing our StemSpine® treatment for lower back pain and filing an Innovative New Drug (IND) application to the FDA utilizing our ImmCelz technology platform to treat stroke. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products such as Ovastem™ that utilize our proprietary intellectual property.   Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2021 and for the three-month period then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results for the full year.   Going Concern – The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the three-month period ended March 31, 2021, the Company had negative cash flows from operating activities of $441,518 and had a working capital deficit of $3,039,315. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.   Risks and Uncertainties - On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.   Revenue - We have adopted the new revenue recognition standards that went into effect on January 1, 2019. All revenues reported in 2019 and beyond reflect those standards. Adoption of the standards had no effect on the Company’s revenues.   Fair Value of Financial Instruments - The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.   When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2021, and December 31, 2020, the Company didn’t have any Level 1 or 2 financial instruments. The table below reflects the results of our Level 3 fair value calculations:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Notes</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Warrants</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Derivative liability at December 31, 2020</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,343,835</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,397,997</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,741,832</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Addition of new conversion option derivatives</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">817,791</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">817,791</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Extinguishment/modification</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Conversion of note derivatives</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,124,855 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,124,855 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Change in fair value</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(29,438,447 </td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">279,257</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(29,159,190 </td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Derivative liability at March 31, 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">598,324</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,677,254</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,275,578</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr></table>   Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.   The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the three-months ended March 31, 2021.   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> For the Three Months Ended March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating basic earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,138,560,486</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of Series B and C preferred stock</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of warrants</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,785,779</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,949,143</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of convertible related party management fee and patent liabilities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">234,194</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating diluted earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,244,529,602</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income as reported</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,836,019</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Add - Interest on convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,718</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income available to common stockholders</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">27,889,737</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr></table>    <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> For the Three Months Ended March 31, 2020</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Weighted average common shares outstanding used in calculating basic earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,746,192</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Effect of warrants</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,834,433</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Effect of convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,263,144</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Effect of convertible related party management fee and patent liabilities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168,761,150</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Weighted average common shares outstanding used in calculating diluted earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">776,604,919</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Net income as reported</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,480</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Add - Interest on convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,714</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Net income available to common stockholders</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">3,792,194</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table>   The Company excluded 3,333 options and 8,920,779 warrants from the computation of diluted net income per share for the three-months ended March 31, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.   During the three-month period ended March 31, 2020, the Company had 3,333 options and 209,827 warrants to purchase common stock outstanding. In addition, the Company has various convertible notes payable which on March 31, 2020, are convertible into approximately 562,263,144 shares of common stock.   Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">ED Patent – The Company acquired a patent from CMH. Amortization expense of $2,493 was recorded for the three-month period ended March 31, 2021. As of March 31, 2021, and December 31, 2020, the carrying value of the patent was $48,466 and $50,959, respectively. The Company expects to amortize approximately $9,972 annually through 2026 related to the patent costs.   Multipotent Amniotic Fetal Stem Cells License Agreement - In August 2016, CMT entered into a License Agreement with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of March 31, 2021, and December 31, 2020, no amounts are currently due to the University.   The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $293 was recorded for the three-month period ended March 31, 2021. Amortization expense of $294 was recorded for the three-month period ended March 31, 2020. As of March 31, 2021, and December 31, 2020, the carrying values of the patent were $5,256 and $5,549, respectively. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.   Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> •</td> <td> The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.</td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> •</td> <td> In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $200,000, upon completion of the IRB clinical trial.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $300,00 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> •</td> <td> In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $100,000 upon filing an IND with the FDA.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"></td> <td style="width:4%;vertical-align:top;"> o</td> <td style="vertical-align:top;"> $400,000 upon dosing the first patient in a Phase 3 clinical trial.</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> •</td> <td> Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.</td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> •</td> <td> In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.</td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> •</td> <td style="vertical-align:top;"> For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties. </td></tr></table>   The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $2,500 was recorded for the three-month period ended March 31, 2021. As of March 31, 2021, and December 31, 2020, the carrying value of the initial patent license was $62,500 and $65,000, respectively. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.   In November 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. During the three months ended March 31, 2021, $50,000 of this amount was converted into 44,642,847 shares of the Company’s common stock. As of March 31, 2021, the remaining liability balance was $0. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 was recorded for the three-month period ended March 31, 2021. Amortization expense of $11,485 was recorded for the three-month period ended March 31, 2020, As of March 31, 2021 and December 31, 2020, the carrying value of the patent was $236,769 and $248,254, respectively. The Company expect to amortize approximately $46,000 annually through 2027 related to the patent costs.   ImmCelzTM - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. The Agreement grants to ImmCelzTM the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelzTM access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor and as documented in standard operating procedures (SOPs) and other written documentation. The terms of the agreement are as follows:    <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;">  </td> <td style="width:4%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement</td></tr> <tr style="height:15px"> <td>    </td> <td style="vertical-align:top;"> ·</td> <td style="vertical-align:top;"> Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelzTM. during such calendar quarter (the “Continuing Royalty”)</td></tr> <tr style="height:15px"> <td>    </td> <td style="vertical-align:top;"> ·</td> <td style="vertical-align:top;"> in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.</td></tr></table>   As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above.   The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $6,250 was recorded for the three-month period ended March 31, 2021. There was no amortization expense recorded for the three-month period ended March 31, 2020. As of March 31, 2021, and December 31, 2020, the carrying values of the patent were $243,750 and $250,000, respectively. The Company expects to amortize approximately $25,000 annually through 2030 related to the licensing costs.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2019. Each of the Company’s executive officers is employed by CMH and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. During the three months ended March 31, 2021 and 2020, the Company recorded $135,000 in expense in connection with this agreement.   As of March 31, 2021, and December 31, 2020, amounts due to CMH under the arrangement were $5,082 and $18,782, respectively.   See Note 2 for discussion of an additional related party transaction with CMH.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">During the three-months ended March 31, 2021, we issued $157,150 in convertible notes to accredited investors with net proceeds of $134,640. The notes mature during February of 2022 and bear interest at rate of 8%. The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is amortizing the discount due to derivative liabilities and on-issuance discount totaling $157,150 to interest expense using the straight-line method over the original terms of the loans.   During the three-months ended March 31, 2021 and 2020, the Company amortized $231,232 and $289,825 respectively, to interest expense. As of March 31, 2021, total discounts of $335,568 remained for which will be expensed through February 2022.   During the three-months ended March 31, 2021, the Company issued an aggregate of 314,702,077 shares upon the conversion of $887,560 of outstanding principal, interest and fees on existing, outstanding notes and 10,055,556 shares upon the cashless exercise of 11,583,333 warrants. During the three months ended March 31, 2020, the Company issued an aggregate of 61,016,388 shares upon the conversion of $350,547 of outstanding principal, interest and fees on existing, outstanding notes.    During the three-months ended March 31, 2021 and 2020, the Company did not extinguish any principal or interest.   As of March 31, 2021, future loan maturities are as follows:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> For the year ended December 31,</td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" colspan="2" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">505,642</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> 2022</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">157,150</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Total</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">662,792</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Derivative Liabilities   In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the three-months ended March 31, 2021, the Company recorded initial derivative liabilities of $817,791 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0106 to $0.0138 our stock price on the date of grant of $0.0310 to $0.0138, expected dividend yield of 0%, expected volatility of 98.14%, risk free interest rate of 0.10% and expected terms of 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $683,151, which was recorded as a day one loss in derivative liability.   On March 31, 2021, the derivative liabilities were revalued at $2,275,578 resulting in a gain of $29,159,190 related to the change in fair market value of the derivative liabilities during the three months ended March 31, 2021. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.0008 to 3.0900, our stock price on the date of valuation ($0.0332), expected dividend yield of 0%, expected volatility of 93.05% to 102.96%, risk-free interest rate of 0.07% to 0.35%, and expected terms ranging from 0.5 to 3.3 years.   In connection with convertible notes converted, as disclosed in Note 4, the Company reclassed derivative liabilities with a fair value of $8,124,855 to additional paid-in capital for the three-month period ended March 31, 2021. The Company revalued the derivative liabilities at each conversion date recording the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted to the pre-conversion carrying value to additional paid-in capital.   Future Potential Dilution   Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of March 31, 2021, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 37 million shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">From January 2021 through March 2021, the Company issued no warrants in connection with services and convertible notes payable.   The fair value of each warrant is estimated using the Black-Scholes valuation model on the date of issuance and if needed at each period end. Assumptions used in calculating the fair value during the three months ended March 31, 2021 were as follows:   <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Inputs Used</td> <td>  </td></tr> <tr style="height:15px"> <td>  </td> <td>  </td> <td colspan="2">  </td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Annual dividend yield</td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:1%;"></td> <td style="width:12%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expected life (years)</td> <td>  </td> <td></td> <td> 1.3 to 3.3</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Risk-free interest rate</td> <td>  </td> <td></td> <td> 0.07% to 0.35</td> <td style="vertical-align:bottom;"> %</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expected volatility</td> <td>  </td> <td></td> <td> 93.05% to 102.96</td> <td style="vertical-align:bottom;"> %</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Common stock price</td> <td style="vertical-align:bottom;"> $</td> <td></td> <td>  0.0008 to $3.0900</td> <td>  </td></tr></table>   Since the expected life of the warrants was greater than the Company’s historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies.   The issuances, exercises and pricing re-sets during the three months ended March 31, 2021, are as follows:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding at December 31, 2020</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,369,112</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Issuances</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercises</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,583,333 </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Anti-Dilution/Modification</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Forfeitures/cancellations</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Outstanding at March 31, 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,785,779</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted Average Price at March 31, 2021</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.006</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">Series B Convertible Preferred Stock Equity Financing On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation.   Dividends: Each share of Series B Convertible Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 10% per annum, payable quarterly, beginning on the Original Issuance Date and ending on the date that such share of Series B Convertible Preferred Share has been converted or redeemed (the “Dividend End Date”). Dividends may be paid in cash or in shares of Series B Convertible Preferred Stock. From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series B Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous sentence.   Voting Rights: The Series B Convertible Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not in excess of 4.99% conversion limitation). However, as long as any shares of Series B Convertible Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series B Convertible Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Convertible Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series B Convertible Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series b Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (d) increase the number of authorized shares of Series B Convertible Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.   Liquidation: Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.   Conversion: Each share of Series B Convertible Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value of such share of Series B Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series B Convertible Preferred Stock shall be the amount equal to $0.05 per share. Following the event of a default the conversion price shall be $0.35.   Redemption: The Series B Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 105% of the stated value if the redemption takes place within 90 days of issuance;</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance</td></tr></table>   In addition, the Series B Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages.   Most Favored Nation Provision. From the date hereof until the date when the Holder no longer holds any shares of Series B Preferred Stock, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a “Subsequent Financing”), the Holder may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series B Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. The Company shall provide the Holder with notice of any such Subsequent Financing in the manner set forth below. For purposes of illustration, if a Subsequent Financing were to occur whereby the Company sells and issues a convertible note with a conversion price that includes a discount to the market price of its Common Stock, the Holder will be entitled to receive the same convertible note on the exact same terms on a dollar-for-dollar basis via the exchange of the Series B Preferred Stock the Holder holds on the date of the sale and issuance of the convertible note.   On February 12, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with BHP Capital, LLC (“BHP”) in the amount of $350,000 for 350 shares of the newly-designated Series B Convertible Preferred Stock valued at $1,200 per share for which $326,600 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 1.5 million shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.   Series C Convertible Preferred Stock Equity Financing   On March 30, 2021, the Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation.   Dividends: Each share of Series C Convertible Preferred Stock shall be entitled to receive, and the Corporation shall pay, cumulative dividends of 10% per annum, payable quarterly, beginning on the Original Issuance Date and ending on the date that such share of Series C Convertible Preferred Share has been converted or redeemed (the “Dividend End Date”). Dividends may be paid in cash or in shares of Series C Convertible Preferred Stock. From and after the initial Closing Date, in addition to the payment of dividends pursuant to Section 2(a), each Holder shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series C Convertible Preferred Stock equal to (on an as-if-converted-to-Common-Stock basis) and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. The Corporation shall pay no dividends on shares of the common stock unless it simultaneously complies with the previous sentence.   Voting Rights: The Series C Convertible Preferred Stock will vote together with the common stock on an as converted basis subject to the Beneficial Ownership Limitations (not in excess of 4.99% conversion limitation). However, as long as any shares of Series C Convertible Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series C Convertible Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series C Convertible Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series C Convertible Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series C Convertible Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (d) increase the number of authorized shares of Series C Convertible Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing.   Liquidation: Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series C Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.   Conversion: Each share of Series C Convertible Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of common stock (subject to the limitations) determined by dividing the Stated Value of such share of Series C Convertible Preferred Stock by the Conversion Price. The Conversion Price for the Series C Convertible Preferred Stock shall be the amount equal to $0.05 per share. Following the event of a default the conversion price shall be $0.35.   Redemption: The Series C Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 105% of the stated value if the redemption takes place within 90 days of issuance;</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance</td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;"></td> <td style="width:3%;vertical-align:top;"> ·</td> <td style="vertical-align:top;"> 120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance</td></tr></table>   In addition, the Series C Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages.   Most Favored Nation Provision. From the date hereof until the date when the Holder no longer holds any shares of Series C Preferred Stock, upon any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a “Subsequent Financing”), the Holder may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series C Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. The Company shall provide the Holder with notice of any such Subsequent Financing in the manner set forth below. For purposes of illustration, if a Subsequent Financing were to occur whereby the Company sells and issues a convertible note with a conversion price that includes a discount to the market price of its Common Stock, the Holder will be entitled to receive the same convertible note on the exact same terms on a dollar-for-dollar basis via the exchange of the Series C Preferred Stock the Holder holds on the date of the sale and issuance of the convertible note.   On March 30, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with Fourth Man, LLC (“FM”) in the amount of $150,000. The closing under the SPA consisted of 150 shares of Series C Convertible Preferred Stock, stated value $1,200 per share, issued to FM for a purchase price of $150,000, or $1,000 per share, for which $141,049 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 642,857 shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">In accordance with ASC 855, management reviewed all material events through May 17, 2021, for these financial statements and there are no material subsequent events to report, except as follows:     Conversion Notice   During April and May of 2021, we issued 4,948,065 shares of common stock for the conversion of $97,697 in convertible notes.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"> Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments.   We currently conduct substantially all of our commercial operations through CMT. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 14 locations in the United States and Europe.     In 2020, we formed ImmCelz, Inc., a wholly owned subsidiary of CMT. Through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.    We are currently primarily focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, commercializing our StemSpine® treatment for lower back pain and filing an Innovative New Drug (IND) application to the FDA utilizing our ImmCelz technology platform to treat stroke. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products such as Ovastem™ that utilize our proprietary intellectual property.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2021 and for the three-month period then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results for the full year.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the three-month period ended March 31, 2021, the Company had negative cash flows from operating activities of $441,518 and had a working capital deficit of $3,039,315. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">We have adopted the new revenue recognition standards that went into effect on January 1, 2019. All revenues reported in 2019 and beyond reflect those standards. Adoption of the standards had no effect on the Company’s revenues.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.   When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2021, and December 31, 2020, the Company didn’t have any Level 1 or 2 financial instruments. The table below reflects the results of our Level 3 fair value calculations:   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Notes</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Warrants</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Total</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Derivative liability at December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 37,343,835</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,397,997</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 38,741,832</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Addition of new conversion option derivatives</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 817,791</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 817,791</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Extinguishment/modification</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Conversion of note derivatives</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (8,124,855 </td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (8,124,855 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Change in fair value</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (29,438,447 </td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 279,257</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (29,159,190 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Derivative liability at March 31, 2021</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 598,324</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 1,677,254</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 2,275,578</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.   The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the three-months ended March 31, 2021.   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> For the Three Months Ended March 31, 2021</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating basic earnings per share</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 1,138,560,486</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of Series B and C preferred stock</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 12,000,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of warrants</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 64,785,779</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of convertible notes payable</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 28,949,143</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of convertible related party management fee and patent liabilities</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 234,194</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating diluted earnings per share</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 1,244,529,602</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td>  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income as reported</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 27,836,019</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Add - Interest on convertible notes payable</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 53,718</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income available to common stockholders</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 27,889,737</td> <td style="width:1%;">  </td></tr></table>   The Company excluded 3,333 options and 8,920,779 warrants from the computation of diluted net income per share for the three-months ended March 31, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.   During the three-month period ended March 31, 2020, the Company had 3,333 options and 209,827 warrants to purchase common stock outstanding. In addition, the Company has various convertible notes payable which on March 31, 2020, are convertible into approximately 562,263,144 shares of common stock.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN">The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Notes</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Warrants</td> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Total</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Derivative liability at December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 37,343,835</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,397,997</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 38,741,832</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Addition of new conversion option derivatives</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 817,791</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 817,791</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Extinguishment/modification</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Conversion of note derivatives</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (8,124,855 </td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (8,124,855 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Change in fair value</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (29,438,447 </td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 279,257</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (29,159,190 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Derivative liability at March 31, 2021</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 598,324</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 1,677,254</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 2,275,578</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> For the Three Months Ended March 31, 2021</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating basic earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,138,560,486</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of Series B and C preferred stock</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000,000</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of warrants</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,785,779</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Effect of convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,949,143</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Effect of convertible related party management fee and patent liabilities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">234,194</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Weighted average common shares outstanding used in calculating diluted earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,244,529,602</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income as reported</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,836,019</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Add - Interest on convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,718</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Net income available to common stockholders</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">27,889,737</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">  </td></tr></table>    <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> For the Three Months Ended March 31, 2020</td> <td style="white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Weighted average common shares outstanding used in calculating basic earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,746,192</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Effect of warrants</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,834,433</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Effect of convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,263,144</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Effect of convertible related party management fee and patent liabilities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168,761,150</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Weighted average common shares outstanding used in calculating diluted earnings per share</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">776,604,919</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Net income as reported</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,480</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;">Add - Interest on convertible notes payable</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,714</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;">Net income available to common stockholders</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">3,792,194</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table>  </div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> For the year ended December 31,</td> <td style="width:1%;">  </td> <td colspan="2" style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;">  </td> <td colspan="2" style="width:9%;">  </td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> 2021</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 505,642</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> 2022</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 157,150</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Total</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 662,792</td> <td style="width:1%;">  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Inputs Used</td> <td>  </td></tr> <tr style="height:15px"> <td>  </td> <td>  </td> <td colspan="2">  </td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Annual dividend yield</td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:1%;"></td> <td style="width:12%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expected life (years)</td> <td>  </td> <td></td> <td> 1.3 to 3.3</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Risk-free interest rate</td> <td>  </td> <td></td> <td> 0.07% to 0.35</td> <td style="vertical-align:bottom;"> %</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expected volatility</td> <td>  </td> <td></td> <td> 93.05% to 102.96</td> <td style="vertical-align:bottom;"> %</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Common stock price</td> <td style="vertical-align:bottom;"> $</td> <td></td> <td>  0.0008 to $3.0900</td> <td>  </td></tr></table></div>

<div style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding at December 31, 2020</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 76,369,112</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Issuances</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercises</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (11,583,333 </td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Anti-Dilution/Modification</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Forfeitures/cancellations</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Outstanding at March 31, 2021</td> <td style="width:1%;">  </td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 64,785,779</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Weighted Average Price at March 31, 2021</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.006</td> <td style="width:1%;">  </td></tr></table></div>

38741832

817791

-8124855

-29159190

2275578

37343835

817791

-8124855

-29438447

598324

1397997

279257

1677254

40746192

1138560486

12000000

4834433

64785779

562263144

28949143

168761150 234194

776604919

1244529602

3742480

27836019

49714

53718

3792194

27889737

-3039315

562263144

3333

8920779

3333 209827 250000 The "Upfront Royalty”, which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement.

2493

48466

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz. during such calendar quarter (the “Continuing Royalty”)

P10Y

6250

25000

2030 250000

243750

250000

11485

248254

236769

2027 46000 300000 100000 0.3

50000

0.01

44642847

2500

65000

62500

2027 10000 2026

293

294

5256

5549

1172

50959

9972 2026 100000 200000 300000 100000 200000 400000 0.05 0.5

35000

45000 35000 0.3 P20D P30D

5082

18782

135000

505642

157150

662792

314702077 61016388

887560

350547

157150

10055556 11583333

335568

134640

157150

The notes mature during February through September of 2022

0.08

0.6

0.71

817791

2275578

29159190

683151 37000000

0.0029

0.0138

0.0310

0.001

0.0007

0.0035

0.9814

P1Y

P5M30D

P3Y3M18D

0.0008

3.0900

0.0106

0.0138

0.9305

1.0296

P1Y3M18D

P3Y3M18D

0.0007

0.0035

0.9305

1.0296

0.0008

3.0900

76369112

-11583333

64785779

0.006

350 On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock.

1200

350000

0.05

350 326600

1200

1500000

The Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock.

0.001

1200

1.25

642857

0.1 150000 150000

0.001

1200

150 141049

4948065

97697

EX-101.SCH 7 celz-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 celz-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Ex Transition Period Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Preferred Stock Series B [Member] Preferred Stock Series C [Member] Preferred Stock Series A [Member] ASSETS CURRENT ASSETS Cash Total Current Assets [Assets, Current] OTHER ASSETS Licenses, net of amortization TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable Accrued expenses Management fee and patent liabilities - related parties Convertible notes payable, net of discount of $335,567 and $409,649, respectively Advances from related party Derivative liabilities Total Current Liabilities [Liabilities, Current] Commitments and contingencies STOCKHOLDERS' DEFICIT Preferred stock value Common stock, $0.001 par value, 6,000,000,000 shares authorized; 1,140,083,954 and 768,540,617 issued and 1,140,079,954 and 768,536,617 outstanding at March 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT [Liabilities and Equity] Preferred Stock Series C [Member] Preferred Stock Series B [Member] [Preferred Stock Series B [Member]] Preferred Stock Series A [Member] Preferred Class A [Member] Debt discount, convertible notes payable Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, shares par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Cost of revenues Gross profit [Gross Profit] OPERATING EXPENSES Selling, general and administrative Amortization of patent costs TOTAL EXPENSES [Operating Expenses] Operating loss [Operating Income (Loss)] OTHER INCOME/(EXPENSE) Interest expense [Interest Expense] Gain loss on extinguishment of convertible notes Change in fair value of derivatives liabilities Total other income (expense) [Nonoperating Income (Expense)] INCOME BEFORE PROVISION FOR INCOME TAXES Provision for income taxes NET INCOME [Net Income (Loss) Attributable to Parent] BASIC NET INCOME PER SHARE DILUTED NET INCOME PER SHARE WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net income Adjustments to reconcile net loss to net cash from operating activities: Amortization Amortization of debt discounts Change in fair value of derivatives liabilities [Change in fair value of derivatives liabilities] Increase in principal and accrued interest balances due to penalty provision Changes in assets and liabilities: Accounts receivable Inventory Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Management fee payable Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from convertible notes payable Proceeds from sale of preferred stock Related party advances Net cash provided from financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE (DECREASE) IN CASH [Cash and Cash Equivalents, Period Increase (Decrease)] BEGINNING CASH BALANCE ENDING CASH BALANCE SUPPLEMENTAL CASH FLOW INFORMATION: Cash payments for interest Cash payments for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of notes payable, accrued interest and derivative liabilities into common stock Conversion of management fees and patent liability into common stock Discounts on convertible notes payable due to derivative liabilities UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Equity Components [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Common stock issued for related party management liabilities, shares Common stock issued for related party management liabilities, amount Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount Relief of derivative liabilities Difference in shares from reverse stock split, shares Difference in shares from reverse stock split, amount Net income [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Proceeds from sales of preferred stock, shares Proceeds from sales of preferred stock, amount Dividends on preferred stock Cashless exercise of warrants, shares Cashless exercise of warrants, amount Balance, amount Balance, shares ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES LICENSING AGREEMENTS NOTE 2 - LICENSING AGREEMENTS RELATED PARTY TRANSACTIONS NOTE 3 - RELATED PARTY TRANSACTIONS DEBT NOTE 4 - DEBT DERIVATIVE LIABILITIES NOTE 5 - DERIVATIVE LIABILITIES WARRANTS NOTE 6 - WARRANTS STOCKHOLDERS DEFICIT NOTE 7 - STOCKHOLDERS' DEFICIT SUBSEQUENT EVENTS NOTE 8 - SUBSEQUENT EVENTS Organization Use of Estimates Basis of Presentation Going Concern Risks and Uncertainties Revenue Fair Value of Financial Instruments Basic and Diluted Loss Per Share Recent Accounting Pronouncements Schedule of Fair Value Summary of outstanding securities Schedule of future loan maturities WARRANTS (Tables) Schedule of Warrants Schedule of fair value of warrants Derivative Instrument Risk Axis Class Of Warrant Or Right Axis Notes [Member] Warrants [Member] Derivative liability, beginning [Derivative Liability] Addition of new conversion option derivatives Extinguishment/modification Conversion of note derivatives Change in fair value Derivative liability, ending Weighted average common shares outstanding used in calculating basic earnings per share Effect of Series B and C preferred stock Effect of warrants EX-101.CAL 9 celz-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 10 celz-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 11 celz-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Ex Transition Period	true
Entity Common Stock Shares Outstanding		1,142,048,685
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 275,134	$ 98,012
Total Current Assets	275,134	98,012
OTHER ASSETS
Licenses, net of amortization	596,742	619,763
TOTAL ASSETS	871,876	717,775
CURRENT LIABILITIES
Accounts payable	356,001	350,899
Accrued expenses	67,763	159,771
Management fee and patent liabilities - related parties	255,082	468,782
Convertible notes payable, net of discount of $335,567 and $409,649, respectively	327,225	788,701
Advances from related party	32,800	10,800
Derivative liabilities	2,275,578	38,741,832
Total Current Liabilities	3,314,449	40,520,785
Commitments and contingencies	0	0
STOCKHOLDERS' DEFICIT
Preferred stock value	0	0
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 1,140,083,954 and 768,540,617 issued and 1,140,079,954 and 768,536,617 outstanding at March 31, 2021 and December 31, 2020, respectively	1,140,080	768,536
Additional paid-in capital	30,000,915	21,315,690
Accumulated deficit	(34,054,217)	(61,890,236)
TOTAL STOCKHOLDERS' DEFICIT	(2,442,573)	(39,803,010)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	871,876	717,775
Preferred Stock Series B [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	326,600	0
Preferred Stock Series C [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	141,049	0
Preferred Stock Series A [Member]
STOCKHOLDERS' DEFICIT
Preferred stock value	$ 3,000	$ 3,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Debt discount, convertible notes payable	$ 335,567	$ 409,649
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	1,140,083,954	768,540,617
Common stock, shares outstanding	1,140,079,954	768,536,617
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	7,000,000	7,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock Series C [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500	500
Preferred stock, shares issued	150	0
Preferred stock, shares outstanding	150	0
Preferred stock, liquidation preference	$ 180,000	$ 0
Preferred Stock Series B [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	350	0
Preferred stock, shares outstanding	350	0
Preferred stock, liquidation preference	$ 420,000	$ 0
Preferred Stock Series A [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 42,100
Cost of revenues	0	14,196
Gross profit	0	27,904
OPERATING EXPENSES
Selling, general and administrative	280,923	346,168
Amortization of patent costs	23,021	16,772
TOTAL EXPENSES	303,944	362,940
Operating loss	(303,944)	(335,036)
OTHER INCOME/(EXPENSE)
Interest expense	(336,076)	(323,223)
Gain loss on extinguishment of convertible notes	0	0
Change in fair value of derivatives liabilities	28,476,039	4,400,739
Total other income (expense)	28,139,963	4,077,516
INCOME BEFORE PROVISION FOR INCOME TAXES	27,836,019	3,742,480
Provision for income taxes	0	0
NET INCOME	$ 27,836,019	$ 3,742,480
BASIC NET INCOME PER SHARE	$ 0.02	$ 0.09
DILUTED NET INCOME PER SHARE	$ 0.02	$ 0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC	1,138,560,486	40,746,192
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED	1,244,529,602	776,604,919

XML 16 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 27,836,019	$ 3,742,480
Adjustments to reconcile net loss to net cash from operating activities:
Amortization	23,021	16,772
Amortization of debt discounts	231,232	289,825
Change in fair value of derivatives liabilities	(28,476,039)	(4,400,739)
Increase in principal and accrued interest balances due to penalty provision	93,821	0
Changes in assets and liabilities:
Accounts receivable	0	(2,800)
Inventory	0	(2,800)
Accounts payable	5,102	65,780
Accrued expenses	9,026	46,898
Management fee payable	(163,700)	49,263
Net cash used in operating activities	(441,518)	(195,321)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	134,640	145,000
Proceeds from sale of preferred stock	462,000	0
Related party advances	22,000	0
Net cash provided from financing activities	618,640	145,000
NET INCREASE (DECREASE) IN CASH	177,122	(50,321)
BEGINNING CASH BALANCE	98,012	88,648
ENDING CASH BALANCE	275,134	38,327
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	0	6,000
Cash payments for income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued interest and derivative liabilities into common stock	9,012,418	1,101,764
Conversion of management fees and patent liability into common stock	50,000	45,000
Discounts on convertible notes payable due to derivative liabilities	$ 134,640	$ 145,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2019		3,000,000			22,489,046
Balance, amount at Dec. 31, 2019	$ (8,071,499)	$ 3,000	$ 0	$ 0	$ 22,489	$ 17,468,018	$ (25,565,006)
Common stock issued for related party management liabilities, shares					2,250,000
Common stock issued for related party management liabilities, amount	45,000	$ 0	$ 0	$ 0	$ 2,250	42,750	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					61,016,388
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	350,547	$ 0	$ 0	$ 0	$ 61,016	289,531	0
Relief of derivative liabilities	751,217	$ 0	$ 0	$ 0	$ 0	751,217	0
Difference in shares from reverse stock split, shares					1,293
Difference in shares from reverse stock split, amount	0	$ 0	$ 0	$ 0	$ 2	(2)	0
Net income	3,742,480	0	0	0	0	0	3,742,480
Balance, amount at Mar. 31, 2020	(3,182,255)	$ 3,000	$ 0	$ 0	$ 85,757	18,551,514	(21,822,526)
Balance, shares at Mar. 31, 2020		3,000,000			85,756,727
Balance, shares at Dec. 31, 2020		3,000,000			768,536,617
Balance, amount at Dec. 31, 2020	(39,803,010)	$ 3,000	$ 0	$ 0	$ 768,536	21,315,690	(61,890,236)
Common stock issued for related party management liabilities, shares					44,642,847
Common stock issued for related party management liabilities, amount	50,000	$ 0	$ 0	$ 0	$ 44,643	5,357	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					314,702,077
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	887,563	$ 0	$ 0	$ 0	$ 314,702	572,861	0
Relief of derivative liabilities	8,124,855	0	0	0	0	8,124,855	0
Net income	27,836,019	$ 0	$ 0	$ 0	$ 0	0	27,836,019
Proceeds from sales of preferred stock, shares			350	150	2,142,857
Proceeds from sales of preferred stock, amount	462,000	$ 0	$ 321,000	$ 141,000	$ 2,143	(2,143)	0
Dividends on preferred stock	0	$ 0	$ 5,600	$ 49	$ 0	(5,649)	0
Cashless exercise of warrants, shares					10,055,556
Cashless exercise of warrants, amount	0	$ 0	$ 0	$ 0	$ 10,056	(10,056)	0
Balance, amount at Mar. 31, 2021	$ (2,442,573)	$ 3,000	$ 326,600	$ 141,049	$ 1,140,080	$ 30,000,915	$ (34,054,217)
Balance, shares at Mar. 31, 2021		3,000,000	350	150	1,140,079,954

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2021

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	Notes			Warrants		Total
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832
Addition of new conversion option derivatives		817,791			-		817,791
Extinguishment/modification		-			-		-
Conversion of note derivatives		(8,124,855	)		-		(8,124,855	)
Change in fair value		(29,438,447	)		279,257		(29,159,190	)
Derivative liability at March 31, 2021	$	598,324		$	1,677,254	$	2,275,578

	For the Three Months Ended March 31, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		1,138,560,486
Effect of Series B and C preferred stock		12,000,000
Effect of warrants		64,785,779
Effect of convertible notes payable		28,949,143
Effect of convertible related party management fee and patent liabilities		234,194
Weighted average common shares outstanding used in calculating diluted earnings per share		1,244,529,602

Net income as reported	$	27,836,019
Add - Interest on convertible notes payable		53,718
Net income available to common stockholders	$	27,889,737

	For the Three Months Ended March 31, 2020
Weighted average common shares outstanding used in calculating basic earnings per share		40,746,192
Effect of warrants		4,834,433
Effect of convertible notes payable		562,263,144
Effect of convertible related party management fee and patent liabilities		168,761,150
Weighted average common shares outstanding used in calculating diluted earnings per share		776,604,919

Net income as reported	$	3,742,480
Add - Interest on convertible notes payable		49,714
Net income available to common stockholders	$	3,792,194

XML 19 R8.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS

3 Months Ended

Mar. 31, 2021

LICENSING AGREEMENTS

NOTE 2 - LICENSING AGREEMENTS

	•	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	•	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.

$200,000, upon completion of the IRB clinical trial.

$300,00 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

•

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

$100,000 upon filing an IND with the FDA.

$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.

$400,000 upon dosing the first patient in a Phase 3 clinical trial.

	•	Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.
	•	In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.
	•	For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above.

XML 20 R9.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	3 Months Ended
RELATED PARTY TRANSACTIONS	Mar. 31, 2021
RELATED PARTY TRANSACTIONS
NOTE 3 - RELATED PARTY TRANSACTIONS	The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2019. Each of the Company’s executive officers is employed by CMH and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. During the three months ended March 31, 2021 and 2020, the Company recorded $135,000 in expense in connection with this agreement. As of March 31, 2021, and December 31, 2020, amounts due to CMH under the arrangement were $5,082 and $18,782, respectively. See Note 2 for discussion of an additional related party transaction with CMH.

XML 21 R10.htm IDEA: XBRL DOCUMENT

DEBT

3 Months Ended

Mar. 31, 2021

DEBT

NOTE 4 - DEBT

During the three-months ended March 31, 2021 and 2020, the Company did not extinguish any principal or interest.

As of March 31, 2021, future loan maturities are as follows:

For the year ended December 31,

2021		505,642
2022		157,150
Total	$	662,792

XML 22 R11.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES	3 Months Ended
DERIVATIVE LIABILITIES	Mar. 31, 2021
DERIVATIVE LIABILITIES
NOTE 5 - DERIVATIVE LIABILITIES	Derivative Liabilities In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the three-months ended March 31, 2021, the Company recorded initial derivative liabilities of $817,791 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0106 to $0.0138 our stock price on the date of grant of $0.0310 to $0.0138, expected dividend yield of 0%, expected volatility of 98.14%, risk free interest rate of 0.10% and expected terms of 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $683,151, which was recorded as a day one loss in derivative liability. On March 31, 2021, the derivative liabilities were revalued at $2,275,578 resulting in a gain of $29,159,190 related to the change in fair market value of the derivative liabilities during the three months ended March 31, 2021. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.0008 to 3.0900, our stock price on the date of valuation ($0.0332), expected dividend yield of 0%, expected volatility of 93.05% to 102.96%, risk-free interest rate of 0.07% to 0.35%, and expected terms ranging from 0.5 to 3.3 years. In connection with convertible notes converted, as disclosed in Note 4, the Company reclassed derivative liabilities with a fair value of $8,124,855 to additional paid-in capital for the three-month period ended March 31, 2021. The Company revalued the derivative liabilities at each conversion date recording the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted to the pre-conversion carrying value to additional paid-in capital. Future Potential Dilution Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of March 31, 2021, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 37 million shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

XML 23 R12.htm IDEA: XBRL DOCUMENT

WARRANTS

3 Months Ended

Mar. 31, 2021

WARRANTS

NOTE 6 - WARRANTS

From January 2021 through March 2021, the Company issued no warrants in connection with services and convertible notes payable.

		Weighted Average Inputs Used

Annual dividend yield	$		-
Expected life (years)			1.3 to 3.3
Risk-free interest rate			0.07% to 0.35	%
Expected volatility			93.05% to 102.96	%
Common stock price	$		0.0008 to $3.0900

The issuances, exercises and pricing re-sets during the three months ended March 31, 2021, are as follows:

Outstanding at December 31, 2020		76,369,112
Issuances		-
Exercises		(11,583,333	)
Anti-Dilution/Modification		-
Forfeitures/cancellations		-
Outstanding at March 31, 2021		64,785,779
Weighted Average Price at March 31, 2021	$	0.006

XML 24 R13.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT

3 Months Ended

Mar. 31, 2021

STOCKHOLDERS DEFICIT

NOTE 7 - STOCKHOLDERS' DEFICIT

Series B Convertible Preferred Stock Equity Financing

Redemption: The Series B Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.

105% of the stated value if the redemption takes place within 90 days of issuance;

110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance

120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance

Series C Convertible Preferred Stock Equity Financing

Liquidation: Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Series C Convertible Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

Redemption: The Series C Convertible Preferred Stock may be redeemed by payment of the stated value thereof, with the following premiums based on the time of the redemption.

105% of the stated value if the redemption takes place within 90 days of issuance;

110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance

120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2021
SUBSEQUENT EVENTS
NOTE 8 - SUBSEQUENT EVENTS	In accordance with ASC 855, management reviewed all material events through May 17, 2021, for these financial statements and there are no material subsequent events to report, except as follows: Conversion Notice During April and May of 2021, we issued 4,948,065 shares of common stock for the conversion of $97,697 in convertible notes.

XML 26 R15.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2021

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2021 and for the three-month period then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three-month period ended March 31, 2021, are not necessarily indicative of the operating results for the full year.

Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, during the three-month period ended March 31, 2021, the Company had negative cash flows from operating activities of $441,518 and had a working capital deficit of $3,039,315. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Risks and Uncertainties

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

Revenue

We have adopted the new revenue recognition standards that went into effect on January 1, 2019. All revenues reported in 2019 and beyond reflect those standards. Adoption of the standards had no effect on the Company’s revenues.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

	Notes			Warrants		Total
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832
Addition of new conversion option derivatives		817,791			-		817,791
Extinguishment/modification		-			-		-
Conversion of note derivatives		(8,124,855	)		-		(8,124,855	)
Change in fair value		(29,438,447	)		279,257		(29,159,190	)
Derivative liability at March 31, 2021	$	598,324		$	1,677,254	$	2,275,578

Basic and Diluted Loss Per Share

The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

	For the Three Months Ended March 31, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		1,138,560,486
Effect of Series B and C preferred stock		12,000,000
Effect of warrants		64,785,779
Effect of convertible notes payable		28,949,143
Effect of convertible related party management fee and patent liabilities		234,194
Weighted average common shares outstanding used in calculating diluted earnings per share		1,244,529,602

Net income as reported	$	27,836,019
Add - Interest on convertible notes payable		53,718
Net income available to common stockholders	$	27,889,737

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

XML 27 R16.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2021

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of Fair Value

	Notes			Warrants		Total
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832
Addition of new conversion option derivatives		817,791			-		817,791
Extinguishment/modification		-			-		-
Conversion of note derivatives		(8,124,855	)		-		(8,124,855	)
Change in fair value		(29,438,447	)		279,257		(29,159,190	)
Derivative liability at March 31, 2021	$	598,324		$	1,677,254	$	2,275,578

Summary of outstanding securities

	For the Three Months Ended March 31, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		1,138,560,486
Effect of Series B and C preferred stock		12,000,000
Effect of warrants		64,785,779
Effect of convertible notes payable		28,949,143
Effect of convertible related party management fee and patent liabilities		234,194
Weighted average common shares outstanding used in calculating diluted earnings per share		1,244,529,602

Net income as reported	$	27,836,019
Add - Interest on convertible notes payable		53,718
Net income available to common stockholders	$	27,889,737

	For the Three Months Ended March 31, 2020
Weighted average common shares outstanding used in calculating basic earnings per share		40,746,192
Effect of warrants		4,834,433
Effect of convertible notes payable		562,263,144
Effect of convertible related party management fee and patent liabilities		168,761,150
Weighted average common shares outstanding used in calculating diluted earnings per share		776,604,919

Net income as reported	$	3,742,480
Add - Interest on convertible notes payable		49,714
Net income available to common stockholders	$	3,792,194

XML 28 R17.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

3 Months Ended

Mar. 31, 2021

DEBT

Schedule of future loan maturities

For the year ended December 31,

2021		505,642
2022		157,150
Total	$	662,792

XML 29 R18.htm IDEA: XBRL DOCUMENT

WARRANTS (Tables)

3 Months Ended

Mar. 31, 2021

WARRANTS (Tables)

Schedule of Warrants

		Weighted Average Inputs Used

Annual dividend yield	$		-
Expected life (years)			1.3 to 3.3
Risk-free interest rate			0.07% to 0.35	%
Expected volatility			93.05% to 102.96	%
Common stock price	$		0.0008 to $3.0900

Schedule of fair value of warrants

Outstanding at December 31, 2020		76,369,112
Issuances		-
Exercises		(11,583,333	)
Anti-Dilution/Modification		-
Forfeitures/cancellations		-
Outstanding at March 31, 2021		64,785,779
Weighted Average Price at March 31, 2021	$	0.006

XML 30 R19.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Mar. 31, 2021 USD ($)
Derivative liability, beginning	$ 38,741,832
Addition of new conversion option derivatives	817,791
Extinguishment/modification	0
Conversion of note derivatives	(8,124,855)
Change in fair value	(29,159,190)
Derivative liability, ending	2,275,578
Warrants [Member]
Derivative liability, beginning	1,397,997
Addition of new conversion option derivatives	0
Extinguishment/modification	0
Conversion of note derivatives	0
Change in fair value	279,257
Derivative liability, ending	1,677,254
Notes [Member]
Derivative liability, beginning	37,343,835
Addition of new conversion option derivatives	817,791
Extinguishment/modification	0
Conversion of note derivatives	(8,124,855)
Change in fair value	(29,438,447)
Derivative liability, ending	$ 598,324

XML 31 R20.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Weighted average common shares outstanding used in calculating basic earnings per share	1,138,560,486	40,746,192
Effect of Series B and C preferred stock	12,000,000
Effect of warrants	64,785,779	4,834,433
Effect of convertible notes payable	28,949,143	562,263,144
Effect of convertible related party management fee and patent liabilities	234,194	168,761,150
Weighted average common shares outstanding used in calculating diluted earnings per share	1,244,529,602	776,604,919
Net income as reported	$ 27,836,019	$ 3,742,480
Add - Interest on convertible notes payable	53,718	49,714
Net income available to common stockholders	$ 27,889,737	$ 3,792,194

XML 32 R21.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Working capital deficit	$ (3,039,315)
Debt conversion, converted instrument, shares issued		562,263,144
Cash used in operating activity	$ (441,518)	$ (195,321)
Warrants [Member]
Anti-dilutive securities excluded from computation of earning per share	8,920,779
Warrants to purchase common stock outstanding		209,827
Options [Member]
Anti-dilutive securities excluded from computation of earning per share	3,333
Options to purchase common stock outstanding		3,333

XML 33 R22.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Dec. 28, 2020	Nov. 30, 2019	May 17, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
License fees	$ 250,000
License agreement description	The "Upfront Royalty”, which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement.
Continuing royalty description				Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz. during such calendar quarter (the “Continuing Royalty”)
Amortization expenses				$ 23,021	$ 16,772
Finite-Lived Intangible Assets, Net				596,742		$ 619,763
Debt conversion, converted instrument, shares issued					562,263,144
Stemspine LLC [Member]
Royalty payment percentage			5.00%
Non-royalty sublease income percentage.			50.00%
Patent License Agreement [Member]
License fees				250,000
Amortization expenses				6,250
Finite-Lived Intangible Assets, Net				$ 25,000
Expiration period of finite-lived intangible assets				2030
Amortization period				10 years
Patent, carrying value				$ 243,750		250,000
Patents [Member]
Amortization expenses				2,493
Finite-Lived Intangible Assets, Net				48,466		50,959
Expected amount of amortization				$ 9,972
Expiration period of finite-lived intangible assets				2026
Patents [Member] \| Creative Medical Health Inc [Member]
Amortization expenses				$ 11,485
Finite-Lived Intangible Assets, Net				236,769		248,254
Expected amount of amortization				$ 46,000
Expiration period of finite-lived intangible assets				2027
Initial payment		$ 300,000	$ 100,000
Percentage of discount on the basis of recent trading price			30.00%
Debt conversion, converted instrument, amount				$ 50,000
Share price for two or more consecutive trading days			$ 0.01
Debt conversion, converted instrument, shares issued				44,642,847
Patents [Member] \| Creative Medical Health Inc [Member] \| Scenario One [Member]
Payments upon signing agreement with university for the initiation of an IRB clinical trial			$ 100,000
Payments upon completion of the IRB clinical trial			200,000
Payments in the event of commercialization of technology			300,000
Patents [Member] \| Creative Medical Health Inc [Member] \| Scenario Two [Member]
Payments upon filing an IND with the FDA			100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial			200,000
Payments upon dosing of the first patient in Phase 3 clinical trial			$ 400,000
Patents [Member] \| Stemspine LLC [Member]
Amortization expenses				$ 2,500
Finite-Lived Intangible Assets, Net				62,500		65,000
Expected amount of amortization				$ 10,000
Expiration period of finite-lived intangible assets				2027
Patents [Member] \| Multipotent Amniotic Fetal Stem Cells License Agreement [Member]
Amortization expenses				$ 293	$ 294
Finite-Lived Intangible Assets, Net				5,256		$ 5,549
Expected amount of amortization				$ 1,172
Expiration period of finite-lived intangible assets				2026

XML 34 R23.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Dec. 31, 2018	Nov. 17, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Creative Medical Health [Member]
Percentage of Common Stock, Discount on Shares at the market price.		30.00%
Number of Trading days		20 days
Agreement Notice period		30 days
Amounts due under the arrangement			$ 5,082		$ 18,782
Expense			135,000	$ 135,000
Maximum [Member]
Represent the amount of reimbursement of management fees, monthly	$ 45,000
Minimum [Member]
Represent the amount of reimbursement of management fees, monthly	$ 35,000
January 1, 2016 [Member]
Management and consultant service, monthly			$ 35,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

DEBT (Details)	Mar. 31, 2021 USD ($)
For the year ended December 31
2021	$ 505,642
2022	157,150
Total	$ 662,792

XML 36 R25.htm IDEA: XBRL DOCUMENT

DEBT (Details Narrative)	3 Months Ended
DEBT (Details Narrative)	Mar. 31, 2021 USD ($) integer shares	Mar. 31, 2020 USD ($) shares
Debt conversion, shares issued \| shares	314,702,077	61,016,388
Debt conversion, converted instrument, amount	$ 887,560	$ 350,547
Amortization of debt discount	$ 231,232	289,825
Debt conversion, converrted instrument, shares issued \| shares	10,055,556
Common stock issued for cashless warrant exercise, shares \| shares	11,583,333
Unamortized debt discount	$ 335,568
Proceeds from convertible notes payable	134,640	$ 145,000
Convertible Debt [Member] \| Accredited Investors [Member]
Amortization of debt discount	157,150
Proceeds from convertible notes payable	134,640
Convertible notes payable	$ 157,150
Maturity date, description	The notes mature during February through September of 2022
Interest rate	8.00%
Debt instrument, convertible, threshold trading day \| integer	15
Convertible Debt [Member] \| Accredited Investors [Member] \| Minimum [Member]
Conversion price, percentage	60.00%
Convertible Debt [Member] \| Accredited Investors [Member] \| Maximum [Member]
Conversion price, percentage	71.00%

XML 37 R26.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	3 Months Ended
DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Derivative Liability	$ 817,791
Derivative, Gain (Loss) on Derivative, Net	8,124,855	$ 751,217
Derivative liabilities exceeded the face values	$ 683,151
Debt Conversion, Converted Instrument, Shares Issued	37,000,000
Revaluation [Member]
Derivative Liability	$ 2,275,578
Derivative, Gain (Loss) on Derivative, Net	$ 29,159,190
Expected dividend yield	0.00%
Stock price	$ 0.0029
Revaluation [Member] \| Minimum [Member]
Risk free interest	0.07%
Expected volatility rate	93.05%
Expected term	5 months 30 days
Exercise price	$ 0.0008
Revaluation [Member] \| Maximum [Member]
Risk free interest	0.35%
Expected volatility rate	102.96%
Expected term	3 years 3 months 18 days
Exercise price	$ 3.0900
Initial valuation [Member]
Expected dividend yield	0.00%
Risk free interest	0.10%
Expected volatility rate	98.14%
Expected term	1 year
Initial valuation [Member] \| Minimum [Member]
Stock price	$ 0.0138
Exercise price	0.0106
Initial valuation [Member] \| Maximum [Member]
Stock price	0.0310
Exercise price	$ 0.0138

XML 38 R27.htm IDEA: XBRL DOCUMENT

WARRANTS (Details) - Warrants [Member]	3 Months Ended
WARRANTS (Details) - Warrants [Member]	Mar. 31, 2021 USD ($) $ / shares
Annual dividend yield \| $	$ 0
Minimum [Member]
Expected life (years)	1 year 3 months 18 days
Risk-free interest rate	0.07%
Expected volatility	93.05%
Common stock price	$ 0.0008
Maximum [Member]
Expected life (years)	3 years 3 months 18 days
Risk-free interest rate	0.35%
Expected volatility	102.96%
Common stock price	$ 3.0900

XML 39 R28.htm IDEA: XBRL DOCUMENT

WARRANTS (Details 1) - Warrants [Member]	3 Months Ended
WARRANTS (Details 1) - Warrants [Member]	Mar. 31, 2021 $ / shares shares
Outstanding, beginning period	76,369,112
Issuances
Exercises	(11,583,333)
Anti-Dilution/Modification
Forfeitures/cancellations
Outstanding, ending period	64,785,779
Weighted Average Price \| $ / shares	$ 0.006

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)		3 Months Ended
STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	Feb. 12, 2021	Mar. 31, 2021	Mar. 30, 2021	Feb. 11, 2021	Dec. 31, 2020
Common Stock shares issued		1,140,083,954			768,540,617
Series B Preferred Shares [Member]
Preferred stock series, description		On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock.
Stated Value per share				$ 1,200
Conversion price per share		$ 0.05
Common stock price				0.001
Redemption price		125.00%
Preferred Stock Series C [Member]
Preferred stock series, description		The Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock.
Stated Value per share		$ 1,200		$ 1,200
Common stock price		$ 0.001
Redemption price		125.00%
Board of Directors [Member]
Preferred stock shares designated				350
BHP Capital, LLC [Member]
Preferred stock shares designated	350
Common stock price	$ 1,200
Preferred stock shares designated, amount	$ 350,000
Net proceeds	$ 326,600
Stock Issued During Period, Shares, Issued for Services	1,500,000
Fourth Man, LLC [Member]
Preferred stock shares designated			150
Stated Value per share			$ 1,200
Common stock price			$ 0.001
Preferred stock shares designated, amount			$ 150,000
Net proceeds			$ 141,049
Common Stock shares issued		642,857
Cumulative dividends			10.00%
Aggregate purchase price			$ 150,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	May 31, 2021	Mar. 31, 2020
Debt conversion, converted instrument, shares issued		562,263,144
Subsequent Event [Member]
Debt conversion, converted instrument, shares issued	4,948,065
Debt conversion, converted instrument, amount	$ 97,697

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 121 285 1 false 36 0 false 5 false false R1.htm 000001 - Document - Cover Sheet http://jolleymarketing.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://jolleymarketing.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://jolleymarketing.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://jolleymarketing.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://jolleymarketing.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://jolleymarketing.com/role/UnauditedCondensedConsolidatedStatementOfStockholdersDeficit UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LICENSING AGREEMENTS Sheet http://jolleymarketing.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 8 false false R9.htm 000009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://jolleymarketing.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 000010 - Disclosure - DEBT Sheet http://jolleymarketing.com/role/DEBT DEBT Notes 10 false false R11.htm 000011 - Disclosure - DERIVATIVE LIABILITIES Sheet http://jolleymarketing.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 11 false false R12.htm 000012 - Disclosure - WARRANTS Sheet http://jolleymarketing.com/role/WARRANTS WARRANTS Notes 12 false false R13.htm 000013 - Disclosure - STOCKHOLDERS DEFICIT Sheet http://jolleymarketing.com/role/StockholdersDeficit STOCKHOLDERS DEFICIT Notes 13 false false R14.htm 000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://jolleymarketing.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 000017 - Disclosure - DEBT (Tables) Sheet http://jolleymarketing.com/role/DebtTables DEBT (Tables) Tables http://jolleymarketing.com/role/DEBT 17 false false R18.htm 000018 - Disclosure - WARRANTS (Tables) Sheet http://jolleymarketing.com/role/WarrantsTables WARRANTS (Tables) Tables http://jolleymarketing.com/role/WARRANTS 18 false false R19.htm 000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://jolleymarketing.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://jolleymarketing.com/role/LicensingAgreements 22 false false R23.htm 000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://jolleymarketing.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://jolleymarketing.com/role/RelatedPartyTransactions 23 false false R24.htm 000024 - Disclosure - DEBT (Details) Sheet http://jolleymarketing.com/role/DebtDetails DEBT (Details) Details http://jolleymarketing.com/role/DebtTables 24 false false R25.htm 000025 - Disclosure - DEBT (Details Narrative) Sheet http://jolleymarketing.com/role/DebtDetailsNarrative DEBT (Details Narrative) Details http://jolleymarketing.com/role/DebtTables 25 false false R26.htm 000026 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://jolleymarketing.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://jolleymarketing.com/role/DerivativeLiabilities 26 false false R27.htm 000027 - Disclosure - WARRANTS (Details) Sheet http://jolleymarketing.com/role/WarrantsDetails WARRANTS (Details) Details http://jolleymarketing.com/role/WarrantsTables 27 false false R28.htm 000028 - Disclosure - WARRANTS (Details 1) Sheet http://jolleymarketing.com/role/WarrantsDetails1 WARRANTS (Details 1) Details http://jolleymarketing.com/role/WarrantsTables 28 false false R29.htm 000029 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) Sheet http://jolleymarketing.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS DEFICIT (Details Narrative) Details http://jolleymarketing.com/role/StockholdersDeficit 29 false false R30.htm 000030 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://jolleymarketing.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://jolleymarketing.com/role/SubsequentEvents 30 false false All Reports Book All Reports celz-20210331.xml celz-20210331.xsd celz-20210331_cal.xml celz-20210331_def.xml celz-20210331_lab.xml celz-20210331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 47 0001477932-21-003351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-21-003351-xbrl.zip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
ESB-@!>Y!5=&(TXM3T#-6L(]DKE!I; MDIFDW^^UG@?C&(&Y.VD/[Z3GA]FY0H5R#AAUEX9Z-IWAQ&I=* 86RWG8 M#;$W@K8)N9^:25OQ;IP_T 1DC[.GS=_ YFFV7).$QZNET0"LWQN/:J%]6-;L ME4>PT^GO]*T.-,'1ZVC!N7MG'^^=9@.8Y(A5UB9%Q#H]OV7B%KV^>93,&-#= M=BP30NI49*P\5LYOC$BU6)2];I<34K<%'>GN)2!ERM*DTS'CJ5M%2.ZN-,"[ MDCDP2D,6#FFIR:WH9V0_'U=;XZ06VXAA.;KC_""7QLVQ&^9DW!N;8#@Z6T>J M&^?3XI?99O'+'%]G9C>+!UHRXQM= _7[[2E-&KT*:G;NX]MC2?ZFG>G6#-W@ M7#WAG@%#>@:8NB*2C.P1,P.'>^C57>FE'!J=0NL%+WA^BLG9' XF7<>$:Y&R MH&6P_3I[PC<>,ZQ%'_>0^(.@^BF;P]1\AU-1,RR3H[&TX$)UAA%,;D[UH3L6":BJ^"/1)V+WNL )F?1 MZ393+WK12T9,SRS%?7L\G!J -'5)*RZ<.515JM UX-/DD-JD$YD[J@H3*R!@#\?=-@_N(\6MN &2%FA6 MS4(;)FQ^)+N=OTCT!#RF>T5GP"8M M,+F5FW!$.BR*L/H8TZDP>F M$F-BZ>@XT 1GZB-$+L.0- %H&T25S%H!N69,@&A:D>H1A33Z66T?K>72!TO% M#N0!6@D;"\JXQ%S_,[U]N3 A D 1_ ;0':F D(7*(ON2#$ M,/#Q?UHHM\[4(-F\&7T8/;:+>= V;8.E8!]U[:D)?E:G25\]XBU2N^30(B@V M:0*LLR/DX9 C_!."Y$'27I&,MON0)&2AQH;/?K"-4/A&G'\6_NL^QC]C5&$N M)2/593[5@F9Q@:'B*B)G_ Z[G/<=?0EDE/26B_6P\K!IO2![[S$E)U-Y3%B MJ62D1$56*WBUCXG5A:2>?0H\[SX(O\#0WI QJ#6>'=^>1EO:J9TNF-:.;8P] M&/2GX[X)CQEGZD8%^?O=#H;O!/C!H3$09450S%H$GV"8/"'0EN M:8A]U6;:@'RS+O*1KM8&>RK=]K9;LP!^C/2R'=W9X_80\ +H@UW6M@G /KAW MT66=96A,(DMO@RAF.1RW)(?C(WQ727-U:J,Z,\J>H_O%Q+.GM)C45';Z8Q,\ M L_9%Y&K/?B>+JKH!Q-6 ^U,P05RYMN'%*9I#VNW^<;-:*XT?407*RD(&[3! M'DLF@PG<&H#JTZ27;?._)BD\C8!R=ICQ4_#FTY8FX5GO#768XQMN0ZLY=1CX M>LZQK2;VQFUO8,*[T;G[(]6%R.WV+37H?S%HR?""&,E+[NRK*W*,D[.T&YE: M%KTN\C2E9QD=AG!H;(0U7])*"/6AON"!%1!>0)A-0-RM!R-\Q4C.C57XY#Z_ MQ!*X2>@U>O76"5UPZ141)W[^6\O1E;I8ZL^K)F8ED3=A ZOLY >K$%#6,R!, MX$5$8G*B3VBWK=2:K_ZLR2>((U+F^I/[C1E '=CMM7FWD4M5"0T@A. W1GJ9 MHEFITBB>TS*%IFGE"Y;-;/%G=OYW.X-NZ[D$98)5;J$)K<(4:SF]<^\-\F,[ M1\C>^'J3KJ4W"?PZAF'\H'1T"Z65G-EI3>#W*[!%SZY/7N]-.+.EDZ4R NWH MA4 MC5[(96CED$>-&:UU(G*;DC!H=$ZK%;O@ER:D9AZOO=YH8$+"$54YRZ@K\GW8 M!;;KN)8QX369\T3B,4&$)%[(%4>)J.@I472KR#;N-8ICC_DCU7EK7."#+7CO M7&S8N#X\9_\:4[B=WGAD@K%?5S\KEH'<28#/!GR--.TH^.R'"'KN'\C^"%V? M^+.N)!J+,I?&T&"U#A1BA>4L28#N=#)LLRKS4<)6\/>"_X6 Z^?L[=_JW78 M[;&V,H!*!U"4\_*BKO"" M86G8AKZMXJC.Y<'9J %V,DQ'0VA"6;(31*]8RY*F &1MX?L.<01,BO<5W/?V M$2;#NX\%/6OO0>I,K)4+$&4GBA5K -S0V)Q;$\MA+WR+:9W0 M2]QFZ6*9Q7'H;OVY9^AX?@<^H;GD-NV, M!R8D+#A;1\2KPB2G"K7N'@QPU JRSIR_3QI$2:NFK8/: 6B^%H1-4AC![:3= M5 L7Z8QX33#3;.SBYNAU'.L?+$OT1;0/I4[16%)\(4A/P]N#B/G"/I^@CW4M MTM@]0J26+/[%C\6/3VT(H$DK:F58,PU+Z]?9;=*VNKTV _G;[K?:>@[9!_"* MQE\ N^P3P$&(:H:O]"O9Q=N0V O!S2P),:])/6 (SP[O\:A!C:)N!X MX<<(#UV\\G/G'U%8L<@K9P._"I7@6CZ=-Q;%3A3O)#5,B>,7&G1,B/!O*"[' M\0-<@[01@+?A"]TO=&^OR=ET\BK.VC%QBRUU\KA--FDD*88P'#DFY' ]47S9 M1ILV!N(@4SUR[9D \UQJ')(&!ZOY-8'*,@9]P*T7.X]0,37S58,.[)L0/*PJ M9R5!^M/'V7+Q7S-2=!C,EG=@_?G3I]G3W\#J'JP7'Y>+^\7M;+D!L]O;U>?E MAI1Y?UP]+&X7\S7X_@[%&*816!(+*+F.&A%6/,/#8"?WXX/E:O[5\O8VLEFV MQMWKGF5(7CGE5&4W[_P&)(%"%_VBQI5Q^8$K+*W+?8Z9*2=.IVN":XFVCE;T MIAP?.#""]-. ?!OD/DZ"J]+/'_+M@9MW(&KJ8I%7R7N,.$ZG1*#))LH5*[-9 M%GYE.NVTNVT_ DLB5^5 8*3MA.@<&0D%X1AJ"VS$]XYM$"&>PU*M?"<$1)T2 M\Q:$OY,,[?#5C:%WAQRL'Y1U-!FAK@@XF9B'Z>=1T5'>3KNC:9O[O:I\%10P M%F Q'F S)A-T*7)'/[P&)I=W9!\BO)E9=1%%>V1W!>=?TT9T!FP=T[VB'V63 M%IBA;3*TD G>VJ?(7G6XW,:Y@)RKU$)#3>-I>U>I^=RE3;;B(8LOV;
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end